Emergent Biosolutions, Inc. (NYSE:EBS) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.41 by $0.32, Bloomberg Earnings reports. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The business had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. During the same quarter in the previous year, the firm earned $0.56 EPS. The company’s quarterly revenue was up 4.6% compared to the same quarter last year.

Shares of Emergent Biosolutions (EBS) traded up $2.97 during trading hours on Friday, hitting $43.03. The company had a trading volume of 1,630,000 shares, compared to its average volume of 254,771. The firm has a market cap of $1,770.00, a P/E ratio of 23.02, a price-to-earnings-growth ratio of 1.23 and a beta of 1.26. The company has a quick ratio of 6.02, a current ratio of 6.99 and a debt-to-equity ratio of 0.40. Emergent Biosolutions has a 1 year low of $24.70 and a 1 year high of $44.86.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $40.50, for a total transaction of $1,012,500.00. Following the transaction, the chairman now owns 1,555,216 shares of the company’s stock, valued at $62,986,248. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Adam Havey sold 7,885 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $37.06, for a total transaction of $292,218.10. Following the transaction, the executive vice president now directly owns 33,931 shares in the company, valued at approximately $1,257,482.86. The disclosure for this sale can be found here. Insiders sold 180,227 shares of company stock valued at $6,993,970 over the last quarter. Company insiders own 16.50% of the company’s stock.

A number of brokerages recently issued reports on EBS. Wells Fargo & Company reissued an “outperform” rating and set a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. Zacks Investment Research raised Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research report on Wednesday, October 25th. Finally, BidaskClub raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Friday, August 25th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $45.00.

TRADEMARK VIOLATION NOTICE: “Emergent Biosolutions, Inc. (EBS) Releases Quarterly Earnings Results, Beats Estimates By $0.32 EPS” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/04/emergent-biosolutions-inc-ebs-releases-quarterly-earnings-results-beats-estimates-by-0-32-eps.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Earnings History for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.